Association of co-occurring mutations with clinical response and classification of patients from cytogenetic and molecular abnormalities. (A) Tile plot showing the number of co-occurring somatic mutations by gene identified in FoundationOne Heme panel from efficacy-evaluable patients separated by R140 and R172 mIDH2. Only mutated genes occurring in 2 or more patients are shown. Mutations associated with higher risk are in red and mutations associated with lower risk are in green, as defined by Grimwade et al.²⁶  (B) Histogram of the number of mutations identified in each gene from all 100 patient samples analyzed. The number of mutations identified in responding patients are in blue, the number of mutations identified in nonresponding patients are in red, and the number of mutations in patients who were not efficacy evaluable are in gray. (C) Pie charts of proportions of patients in various risk categories according to European LeukemiaNet (ELN) 2010 AML risk stratification,²⁹  ELN 2017 AML risk stratification,²⁸  and Grimwade et al,²⁶  on the basis of cytogenetic testing completed before the start of cycle 2 and mutations identified at screening. (D) Pie chart of proportions of patients in various genomic classifications according to Papaemmanuil et al,¹³  on the basis of cytogenetic testing completed before the start of cycle 2 and mutations identified at screening. CEBPA, CCAAT/enhancer-binding protein alpha; MLL, mixed-lineage leukemia.